Literature DB >> 8463445

Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.

E Metzger1, R Friedman.   

Abstract

Consultation psychiatrists are frequently called upon by their medical and surgical colleagues to assist in the management of agitated, delirious patients in the intensive care unit. Intravenous haloperidol has a reputation for safe and effective sedation of these patients and has been found to be free of many of the dangerous anticholinergic and cardiac side effects of the lower-potency neuroleptics. The authors report the cases of three patients who developed torsades de pointes arrhythmia or lengthening of the Q-T interval during treatment with intravenous haloperidol. The cases suggest that the use of intravenous haloperidol should be accompanied by cardiac monitoring and that risk factors for torsades de pointes during haloperidol treatment may include dilated cardiomyopathy and a history of alcohol abuse.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463445

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  16 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

4.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 5.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 6.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 7.  Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.

Authors:  W Victor R Vieweg; Mark A Wood; Antony Fernandez; Mary Beatty-Brooks; Mehrul Hasnain; Anand K Pandurangi
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

9.  An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.

Authors:  Stefan Dhein; Franziska Perlitz; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

Review 10.  Adverse effects of antipsychotic agents. Do newer agents offer advantages?

Authors:  D G Owens
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.